Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04698031 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Clopidogrel on Incidence of Silent Brain Infarction
A Phase 4 study of Silent Brain Infarction, sponsored by VA Office of Research and Development.
- Active
- Registry status
- Phase 4
- Development phase
- 134
- Enrollment target
- 1
- Study location
NCT04698031 is a Phase 4 study of Silent Brain Infarction that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 134 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04698031, a Phase 4 study of Silent Brain Infarction, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 134 participants
- Enrollment target
- 1
- Study location
Study Summary
Silent brain infarctions (SBIs) are a manifestation of covert cerebrovascular disease, without obvious clinical deficit, noted very often in patients presenting with a new stroke or new transient ischemic attack. SBIs are linked to a significant increase in risk for subsequent stroke and cognitive decline. However, no biomarker is currently available that can predict the recurrence of these subclinical lesions. Coated-platelets are a measure of platelet procoagulant potential significantly increased in patients with ischemic stroke or transient ischemic attack compared to unaffected controls. Higher coated-platelet levels are strongly associated with both the presence and number of SBIs. Among medications approved for preventing stroke recurrence, we identified clopidogrel as a pharmacological agent leading to a decrease in coated-platelet levels. In this project, we plan to evaluate if clopidogrel can decrease the rate of occurrence of new silent brain infarctions. The result will enhance the investigators understanding of the relationship between platelets and silent brain infarcts, leading to improved health care delivery and also potential targets for novel preventive pharmacological interventions.
Conditions Studied
Interventions
- DRUG Clopidogrel treatment
- DRUG Aspirin treatment
Study Locations (1)
Oklahoma
- Oklahoma City VA Medical Center, Oklahoma City, OK - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04698031
The ClinicalTrials.gov registry entry for NCT04698031 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Silent Brain Infarction appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel treatment is the first listed.
NCT04698031 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT04698031 about?
NCT04698031 is a clinical study titled "Efficacy of Clopidogrel on Incidence of Silent Brain Infarction". Silent brain infarctions (SBIs) are a manifestation of covert cerebrovascular disease, without obvious clinical deficit, noted very often in patients presenting with a new stroke or new transient ischemic attack. SBIs are linked to a significant increase in risk for subsequent stroke and cognitive d...
What is the current status of trial NCT04698031?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2022-03-30. Estimated completion is 2026-07-01.
What conditions does trial NCT04698031 study?
This clinical trial studies the following conditions: Silent Brain Infarction.
What interventions are being tested in trial NCT04698031?
The interventions under investigation include: Clopidogrel treatment (DRUG), Aspirin treatment (DRUG).
Who is sponsoring clinical trial NCT04698031?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04698031 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.